Merus N.V. (NASDAQ:MRUS), a biotechnology company specializing in innovative antibody-based therapies with a market capitalization of $2.75 billion, has garnered significant attention from analysts ...

Analysts have hailed Merus’ latest data drop in head and neck cancer as meeting investors’ expectations for the bispecific antibody. The slim slice of efficacy data, which Merus presented at the 2024 ...

Within the last quarter, Merus (NASDAQ:MRUS) has observed the following analyst ratings: In the last 3 months, 10 analysts have offered 12-month price targets for Merus. The company has an average ...

Guggenheim analyst Michael Schmidt has reiterated their bullish stance on MRUS stock, giving a Buy rating on December 2. Don't Miss our Black Friday Offers: Michael Schmidt has given his Buy rating ...

Merus’ NRG1 gene targeting cancer treatment helped to shrink tumors and kept working for up to 9.1 months, leaving the company’s leadership with an important question: partner up or go it alone for ...

Merus (MRUS) keeps catching attention as its shares post impressive gains over the past month, rising around 46%. Recent investor interest appears closely linked to ongoing optimism around the company ...

Merus N.V. (NASDAQ:MRUS) shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in combination with pembrolizumab ...

A targeted cancer therapy from Merus has early clinical trial results suggesting it can treat tumors characterized by a genetic signature that hasn’t been addressed before, and the biotech is eying ...

Merus N.V. (NASDAQ:MRUS) stock moved lower on Monday. The company announced a research collaboration and license agreement with Biohaven Ltd. (NYSE:BHVN). Here’s what you need to know. What To Know: ...

On Wednesday, the FDA approved Merus N.V.’s (NASDAQ:MRUS) Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung ...